Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake

Area of Science:

• Neuroscience
• Addiction Research
• Pharmacology

Background:

• Hypothalamic systems regulating food intake may also influence ethanol consumption.
• Investigating the role of the paraventricular nucleus (PVN) in ethanol intake is crucial for understanding addiction.
• Opioid signaling in the hypothalamus is a potential target for modulating alcohol consumption.

Purpose of the Study:

• To determine if microinjections of morphine and specific opioid agonists into the paraventricular nucleus (PVN) of rats affect ethanol intake.
• To investigate the effects of opioid antagonists, such as naloxone methiodide (m-naloxone), on ethanol consumption.
• To elucidate the specific roles of mu, delta, and kappa opioid receptors in the PVN concerning ethanol intake.

Main Methods:

• Rats were trained to consume ethanol solutions (4% or 7%) without sugar.
• Chronic brain cannulas were implanted targeting the PVN for drug microinjections.
• Morphine, m-naloxone, and specific opioid receptor agonists (DAMGO, DALA, U-50,488H) were administered to assess their effects on ethanol, food, and water intake.
• Anatomical control injections were performed dorsal to the PVN to rule out non-specific effects.

Main Results:

• Microinjection of morphine into the PVN significantly increased ethanol intake, while m-naloxone produced the opposite effect.
• The delta-opioid receptor agonist DALA selectively increased ethanol intake without altering food or water consumption.
• The kappa-opioid agonist U-50,488H decreased ethanol intake, whereas the mu-opioid agonist DAMGO had no significant effect.
• Control injections dorsal to the PVN did not alter intake, confirming the specificity of the PVN effects.

Conclusions:

• Activation of delta-opioid receptors in the PVN enhances ethanol intake, suggesting a role in escalating alcohol consumption.
• Kappa-opioid receptor activation in the PVN suppresses ethanol intake, potentially acting as a counter-regulatory mechanism.
• Endogenous peptides like enkephalin (delta-agonist) may drive ethanol intake escalation via a positive feedback loop in the PVN.
• Dynorphin (kappa-agonist) may counteract this escalation, and naltrexone therapy might function by blocking this opioid-driven cycle.